The effect of activation treatments on the development of reconstructed bovine oocytes.
The purpose of this study was to investigate the effect of different activation treatments on the development of IVM-derived and cloned bovine embryos. The effect of oocyte age (20h versus 24h after IVM) on the blastocyst rate was also investigated. No differences in the percentage of blastocyst development were observed between the oocytes matured for 20 and 24h (15% versus 27%, p>0.05). Reconstructed oocytes activated 4h after fusion (fusion before activation, FBA) had a higher blastocyst rate than those oocytes activated immediately after electrofusion (fusion and activation simultaneously, FAS) (26% versus 5%, p<0.01). Blastocyst rates were significantly greater (p<0.01) for the reconstructed oocytes activated by calcium ionophore (A23187) combined with 6-dimethylaminopurine (6-DMAP) (51.6%) than for those activated with cycloheximide (CHX) plus cytochalasin B (CB) treatment (1h, 8.2%; 5h, 14.3%). However, the blastocyst rates were similar among reconstructed oocytes activated by electric pulses and A23187 (30.5% versus 42.2%) or by A23187 and ionomycin (36.7% versus 33.3%) combined with 6-DMAP, respectively. Blastocysts that developed from reconstructed oocytes activated by A23187 and 6-DMAP resulted in three pregnancies (3/9) and one live birth from 18 embryos transferred to recipient cows. Genotypic analysis of six bovine microsatellite markers by polymerase chain reaction confirmed that the cloned calf was genetically identical to the nuclear donor. In conclusion, reconstructed oocytes that derived from oocytes exposed to activation treatment 4h after electrofusion are more likely to develop to the blastocyst stage. The best treatment to activate reconstructed bovine oocytes in this study was A23187 combined with 6-DMAP.
Shen
P C
PC
Department of Animal Science, National Pingtung University of Science and Technology, Pingtung 912, Taiwan, ROC.
Lee
S N
SN
Liu
B T
BT
Chu
F H
FH
Wang
C H
CH
Wu
J S
JS
Lin
H H
HH
Cheng
W T K
WT
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000367:Age Factors; D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002417:Cattle / Q000196:embryology; D019976:Cloning, Organism / Q000379:methods / Q000662:veterinary*; D003513:Cycloheximide / Q000494:pharmacology; D003571:Cytochalasin B / Q000494:pharmacology; D046149:Embryo Culture Techniques / Q000662:veterinary; D004622:Embryo, Mammalian; D047108:Embryonic Development / Q000187:drug effects*; D005260:Female; D015759:Ionomycin / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D053652:Nuclear Transfer Techniques; D009866:Oogenesis / Q000187:drug effects*; D010312:Parthenogenesis / Q000187:drug effects / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology
D007476:Ionophores; D047428:Protein Kinase Inhibitors; D000001:Calcimycin; D003571:Cytochalasin B; D015759:Ionomycin; C001020:N(6),N(6)-dimethyladenine; D003513:Cycloheximide; D000225:Adenine